$OTLK THIS IS JUST THE BEGINNING FOR OUTLOOK THERAPEUTICS
If you are not familiar with the Stock, get to know it now, it has made investors a lot of money in the past 4 trading days, tripling in value. There is always concerns when it comes to such low cap companies but this rally is based on facts not speculation. After a extremely upbeat drug trial report it was upgraded to $12 the following day by Oppenheimer.
There is no need to worry about missing out on this rally as it has a very long way to g, it was 70% higher on Feb 18th.
A nice entry level is $3.50 just above resistance, with a take profit at $6 below the 200MA.
Average Analysts price target $7
Average Analysts rating BUY
Company Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.
There is no need to worry about missing out on this rally as it has a very long way to g, it was 70% higher on Feb 18th.
A nice entry level is $3.50 just above resistance, with a take profit at $6 below the 200MA.
Average Analysts price target $7
Average Analysts rating BUY
Company Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.